References

1. Rombouts MD, Swart EL, Van Den Eertwegh AJM, Crul M. Systematic review on infusion reactions to and infusion rate of monoclonal antibodies used in cancer treatment. Anticancer Res . 2020;40(3):1201-1218. doi: 10.21873/anticanres.14062.
2. Chung CH. Managing premedications and the risk for reactions to infusional monoclonal antibody therapy. Oncologist . 2008;13(6):725-732. doi: 10.1634/theoncologist.2008-0012.
3. Goto E, Yamaguchi T, Hattori N, et al. Safety of ramucirumab regimen without H1-antihistamine premedication in patients with solid cancers.In Vivo . 2020;34(6):3489-3493. doi: 10.21873/invivo.12189.
4. Kimby E. Tolerability and safety of rituximab (MabThera).Cancer Treat Rev . 2005;31(6):456-473. doi: 10.1016/j.ctrv.2005.05.007.
5. Lenz HJ. Management and preparedness for infusion and hypersensitivity reactions. Oncologist . 2007;12(5):601-609. doi: 10.1634/theoncologist.12-5-601.
6. Dillman RO. Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy. Cancer Metastasis Rev . 1999;18(4):465-471. doi: 10.1023/a:1006341717398.
7. Coussens L, Yang-Feng TL, Liao YC, et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science . 1985;230(4730):1132-1139. doi: 10.1126/science.2999974.
8. Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist . 2009;14(4):320-368. doi: 10.1634/theoncologist.2008-0230.
9. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med . 2001;344(11):783-792. doi: 10.1056/NEJM200103153441101.
10. Moja L, Tagliabue L, Balduzzi S, et al. Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst Rev . 2012;2021(4):CD006243. doi: 10.1002/14651858.CD006243.pub2.
11. von Minckwitz G, Procter M, de Azambuja E, et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med . 2017;377(2):122-131. doi: 10.1056/NEJMoa1703643.
12. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.Lancet . 2010;376(9742):687-697. doi: 10.1016/S0140-6736(10)61121-X.
13. Ryu MH, Yoo C, Kim JG, et al. Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer. Eur J Cancer . 2015;51(4):482-488. doi: 10.1016/j.ejca.2014.12.015.
14. Schechter AL, Stern DF, Vaidyanathan L, et al. The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature . 1984;312(5994):513-516. doi: 10.1038/312513a0.
15. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science . 1987;235(4785):177-182. doi: 10.1126/science.3798106.
16. Okunade G, Green AR, Ying M, et al. Biological profile of oestrogen receptor positive primary breast cancers in the elderly and response to primary endocrine therapy. Crit Rev Oncol Hematol . 2009;72(1):76-82. doi: 10.1016/j.critrevonc.2009.01.005.
17. Valabrega G, Montemurro F, Aglietta M. Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol . 2007;18(6):977-984. doi: 10.1093/annonc/mdl475.
18. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med . 2005;353(16):1659-1672. doi: 10.1056/NEJMoa052306.
19. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med . 2005;353(16):1673-1684. doi: 10.1056/NEJMoa052122.
20. Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol . 2005;23(19):4265-4274. doi: 10.1200/JCO.2005.04.173.
21. Vogel WH. Infusion reactions: diagnosis, assessment, and management.Clin J Oncol Nurs . 2010;14(2):E10-E21. doi: 10.1188/10.CJON.E10-E21.
22. Gomes ER, Demoly P. Epidemiology of hypersensitivity drug reactions.Curr Opin Allergy Clin Immunol . 2005;5(4):309-316. doi: 10.1097/01.all.0000173785.81024.33.
23. Jonker DJ, O’Callaghan CJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med . 2007;357(20):2040-2048. doi: 10.1056/NEJMoa071834.
24. Rugo HS, Im S-AA, Cardoso F, et al. Efficacy of margetuximab vs trastuzumab in patients with pretreated ERBB2-positive advanced breast cancer: A Phase 3 randomized clinical trial. JAMA Oncol . 2021;7(4):573-584. doi: 10.1001/jamaoncol.2020.7932.
25. Adamo V, Ricciardi GRR, Adamo B, et al. The risk of toxicities from trastuzumab, alone or in combination, in an elderly breast cancer population. Oncology . 2014;86(1):16-21. doi: 10.1159/000353450.
26. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol . 2002;20(3):719-726. doi: 10.1200/JCO.2002.20.3.719.
27. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol . 1999;17(9):2639-2648. doi: 10.1200/JCO.1999.17.9.2639.
28. Cook-Bruns N. Retrospective analysis of the safety of Herceptin immunotherapy in metastatic breast cancer. Oncology . 2001;61(suppl 2):58-66. doi: 10.1159/000055403.
29. Pichler WJ. Adverse side-effects to biological agents.Allergy . 2006;61(8):912-920. doi: 10.1111/j.1398-9995.2006.01058.x.
30. Can M, Alibaz-Öner F, Yılmaz-Öner S, Atagündüz P, İnanç N, Direskeneli H. Accelerated infusion rates of rituximab are well tolerated and safe in rheumatology practice: a single-centre experience.Clin Rheumatol . 2013;32(1):87-90. doi: 10.1007/s10067-012-2094-1.
31. van Vollenhoven RF, Emery P, Bingham CO, et al. Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials.J Rheumatol . 2010;37(3):558-567. doi: 10.3899/jrheum.090856.
32. Byrd JC, Murphy T, Howard RS, et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol . 2001;19(8):2153-2164. doi: 10.1200/JCO.2001.19.8.2153.
33. Byrd JC, Waselenko JK, Maneatis TJ, et al. Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance. J Clin Oncol . 1999;17(3):791-795. doi: 10.1200/JCO.1999.17.3.791.
34. Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood . 1999;94(7):2217-2224. doi: 10.1182/blood.V94.7.2217.419k02_2217_2224, http://www.ncbi.nlm.nih.gov/pubmed/10498591.
35. Roselló S, Blasco I, García Fabregat L, Cervantes A, Jordan K, ESMO Guidelines Committee. Management of infusion reactions to systemic anticancer therapy: ESMO Clinical Practice Guidelines. Ann Oncol . 2017;28(suppl_4):iv100-iv118. doi: 10.1093/annonc/mdx216.
36. Breslin S. Cytokine-release syndrome: overview and nursing implications. Clin J Oncol Nurs . 2007;11(1)(suppl):37-42. doi: 10.1188/07.CJON.S1.37-42.
37. Jung JW, Kang HR, Lee SH, Cho SH. The incidence and risk factors of infusion-related reactions to rituximab for treating B cell malignancies in a single tertiary hospital. Oncology . 2014;86(3):127-134. doi: 10.1159/000357711.
38. Kemp SF, Lockey RF, Simons FER, World Allergy Organization ad hoc Committee on Epinephrine in Anaphylaxis. Epinephrine: the drug of choice for anaphylaxis. A statement of the World Allergy Organization.Allergy . 2008;63(8):1061-1070. doi: 10.1111/j.1398-9995.2008.01733.x.
39. Thompson LM, Eckmann K, Boster BL, et al. Incidence, risk factors, and management of infusion-related reactions in breast cancer patients receiving trastuzumab. Oncologist . 2014;19(3):228-234. doi: 10.1634/theoncologist.2013-0286.
40. Tokuda Y, Suzuki Y, Ohta M, et al. Compassionate use of humanized anti-HER2/neu protein, trastuzumab for metastatic breast cancer in Japan. Breast Cancer . 2001;8(4):310-315. doi: 10.1007/BF02967530.
41. Wilke H, Glynne-Jones R, Thaler J, et al. Cetuximab plus irinotecan in heavily pretreated metastatic colorectal cancer progressing on irinotecan: MABEL Study. J Clin Oncol . 2008;26(33):5335-5343. doi: 10.1200/JCO.2008.16.3758.
42. Touma W, Koro SS, Ley J, et al. Risk factors for and pre-medications to prevent cetuximab-induced infusion reactions in patients with squamous cell carcinoma of the head and neck. Oral Oncol . 2014;50(9):895-900. doi: 10.1016/j.oraloncology.2014.06.017.
43. Katanoda K, Hori M, Saito E, et al. Updated trends in cancer in Japan: incidence in 1985-2015 and mortality in 1958-2018-A sign of decrease in cancer incidence. J Epidemiol . 2021;31(7):426-450. doi: 10.2188/jea.JE20200416.
44. Bright CJ, Rea DW, Francis A, Feltbower RG. Comparison of quadrant-specific breast cancer incidence trends in the United States and England between 1975 and 2013. Cancer Epidemiol . 2016;44:186-194. doi: 10.1016/j.canep.2016.08.019.
45. von Elm Ev, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ . 2007;335(7624):806-808. doi: 10.1136/bmj.39335.541782.AD.
46. Enders CK, Tofighi D. Centering predictor variables in cross-sectional multilevel models: a new look at an old issue.Psychol Methods . 2007;12(2):121-138. doi: 10.1037/1082-989X.12.2.121.
47. Merlo J, Chaix B, Ohlsson H, et al. A brief conceptual tutorial of multilevel analysis in social epidemiology: using measures of clustering in multilevel logistic regression to investigate contextual phenomena.J Epidemiol Community Health . 2006;60(4):290-297. doi: 10.1136/jech.2004.029454.
48. Griffin G, Shenoi S, Hughes GC. Hemophagocytic lymphohistiocytosis: an update on pathogenesis, diagnosis, and therapy. Best Pract Res Clin Rheumatol . 2020;34(4):101515. doi: 10.1016/j.berh.2020.101515.
49. Sadaat M, Jang S. Hemophagocytic lymphohistiocytosis with immunotherapy: brief review and case report. J Immunother Cancer . 2018;6(1):49. doi: 10.1186/s40425-018-0365-3.
50. Ma Y, Meng J, Jia J, et al. Current and emerging biological therapy in adult-onset Still’s disease. Rheumatol (Oxf Engl) . 2021;60(9):3986-4000. doi: 10.1093/rheumatology/keab485.
51. Ikegawa K, Suzuki S, Nomura H, et al. Retrospective analysis of premedication, glucocorticosteroids, and H1-antihistamines for preventing infusion reactions associated with cetuximab treatment of patients with head and neck cancer. J Int Med Res . 2017;45(4):1378-1385. doi: 10.1177/0300060517713531.
52. Hayama T, Miura K, Uchiike A, et al. A clinical prediction model for infusion-related reactions to rituximab in patients with B cell lymphomas. Int J Clin Pharm . 2017;39(2):380-385. doi: 10.1007/s11096-017-0429-3.
53. Takahashi M, Takahashi K, Matsumoto S, et al. Low eosinophil percentages as a new predictive marker for infusion reactions due to trastuzumab. Anticancer Res . 2020;40(7):4047-4051. doi: 10.21873/anticanres.14401.
54. Emery P, Fleischmann R, Filipowicz-Sosnowska A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum . 2006;54(5):1390-1400. doi: 10.1002/art.21778.
55. Sumikawa T, Shigeoka Y, Igishi T, et al. Dexamethasone interferes with trastuzumab-induced cell growth inhibition through restoration of AKT activity in BT-474 breast cancer cells. Int J Oncol . 2008;32(3):683-688. doi: 10.3892/ijo.32.3.683, http://www.ncbi.nlm.nih.gov/pubmed/18292946.